NeuroOne Medical Technologies Corporation has announced that it received a notice from Nasdaq granting a 180-day extension, until May 4, 2026, to regain compliance with the stock exchange's minimum bid price requirement of $1.00 per share. The company's shares had previously fallen below this threshold for 30 consecutive business days, triggering a warning in May 2025. While the extension allows NeuroOne's stock to remain listed on the Nasdaq Capital Market for now, failure to meet the requirement by the new deadline could result in a delisting, subject to appeal. The company has stated its intention to take action to regain compliance within the extension period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuroone Medical Technologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-106454), on November 05, 2025, and is solely responsible for the information contained therein.